Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**ACI-15916** is a radiopharmaceutical and diagnostic agent developed by AC Immune SA. It acts as a modulator of monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B), but its primary clinical application is as a positron emission tomography (PET) tracer for detecting abnormal protein deposits, specifically α-synuclein, in the brain. This makes it relevant for diseases such as Parkinson’s disease, Lewy body dementia, and multiple system atrophy—collectively known as α-synucleinopathies. The drug is currently being evaluated in early-phase clinical trials to assess its safety and effectiveness in measuring pathological α-synuclein accumulation[1][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ACI-15916.